filgrastim-sndz Zarxio
Selected indexed studies
- Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. (J Clin Oncol, 2015) [PMID:26169616]
- Zarxio--a filgrastim biosimilar. (Med Lett Drugs Ther, 2016) [PMID:26963154]
- Efficacy of a conversion from filgrastim to filgrastim-sndz in stem cell transplant patients undergoing mobilization. (J Oncol Pharm Pract, 2021) [PMID:32686616]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Filgrastim induced thrombocytopenia. (2020) pubmed
- Zarxio--a filgrastim biosimilar. (2016) pubmed
- Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. (2015) pubmed
- Efficacy of a conversion from filgrastim to filgrastim-sndz in stem cell transplant patients undergoing mobilization. (2021) pubmed
- Real world comparison of filgrastim to filgrastim-sndz in patients with chemotherapy-induced neutropenia. (2026) pubmed
- Totality of the evidence at work: The first U.S. biosimilar. (2016) pubmed
- Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies. (2018) pubmed
- Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. (2017) pubmed
- A single-center, retrospective analysis to compare the efficacy and safety of filgrastim-sndz to filgrastim for prophylaxis of chemotherapy-induced neutropenia and for neutrophil recovery following autologous stem cell transplantation. (2018) pubmed
- A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. (2018) pubmed